ClinicalTrials.gg
CompletedNCT01863186Updated Mar 22, 2022Results posted

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

A Phase 3 interventional study of Lofexidine HCl and Placebo in Opioid Dependence and Acute Opioid Withdrawal Syndrome, sponsored by USWM, LLC (dba US WorldMeds). Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-22.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
603
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing lofexidine in Opioid-Related Disorders — none open to participants now, 1 under way, none of them phase 3. lofexidine · Opioid-Related Disorders.

Enrollment
Largest of 15
603 · median 30
Started
2013
with 1 other
Phase 3
3 of 15
none open now
Registered
10th of 15
by date
Lead sponsor
5 of 15
USWM, LLC (dba US WorldMeds)

Among the 15 studies testing lofexidine in Opioid-Related Disorders, this one has the largest enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 10th registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

None of the 15 studies testing lofexidine in Opioid-Related Disorders is open now. The open studies under Opioid-Related Disorders, anywhere →

Where they have run

About lofexidine

lofexidine: first FDA approval 2018 (LUCEMYRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing lofexidine in Opioid-Related Disorders as a file.
02

Study summary

The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids. The study takes place in 2 parts: a 7-day inpatient double-blind treatment portion where subjects will be randomly assigned to one of three doses of study medication (2.4 mg total daily dose of lofexidine, 3.2 mg total daily dose of lofexidine, or placebo) followed by an optional open-label treatment period where subjects will be inpatient or outpatient and receive lofexidine at variable dosing for up to an additional 7 days. The Investigator hypothesizes that subjects will achieve maximum treatment effect with tolerable side effects at the 3.2 mg total daily dose and that both the 3.2 mg and 2.4 total daily doses will show better efficacy over placebo in treating symptoms of acute opioid withdrawal.

Read the detailed description

This is a Phase 3, two-part, multicenter study to evaluate the dose-response, efficacy, and safety of lofexidine in alleviation of symptoms in subjects undergoing total and abrupt withdrawal from short-acting opioids. Any subject dependent on short-acting opioids (the primary projected indication for lofexidine) about to undergo opioid withdrawal will be eligible. Subjects will be evaluated for their compliance with protocol inclusion/exclusion criteria during a screening period, lasting up to 7 days.

The first part of the study will use an inpatient, randomized, double-blind, and placebo-controlled design (Days 1-7) followed by a second part, an open-label continuation treatment (Days 8-14). A total of 600 subjects will be randomized to receive lofexidine 2.4 mg total daily dose (0.6 mg QID), lofexidine 3.2 mg total daily dose (0.8 mg QID), or matching placebo in a 3:3:2 ratio (225:225:150) for 7 days (i.e., during the most intense stage of withdrawal). During the second part of the study (Days 8-14), all subjects, regardless of their treatment assignment (which will remain double-blinded), who successfully meet the definition for "completer" based on Days 1-7 (i.e., receives at least one dose of study medication on Day 7 and completes the 3.5-hour post-dose SOWS-Gossop assessment on Day 7), will be eligible to receive open-label, variable dose lofexidine treatment (as determined by the Site Investigator, but not to exceed 3.2 mg/day) for up to an additional 7 days in either an inpatient or outpatient setting depending on the wishes of the investigator and the subject. No subject will receive lofexidine for more than 14 days total from the onset of abstinence. There will be no initial dose run-up and no mandated terminal dose taper.

Efficacy and safety assessments will be made daily throughout the study. Safety will be assessed by evaluation of adverse event, clinical labs, electrocardiograms (with special attention to QTc), vital signs, physical exam data, and the Columbia-Suicide Severity Rating Scale. Efficacy will be evaluated daily by subject- and observer-completed scales including the Short Opiate Withdrawal Scale of Gossop (SOWS-G)(the primary outcome measure is SOWS-G score area under the curve for Days 1-7), the Clinical Opiate Withdrawal Scales (COWS), Objective Opiate Withdrawal Scale (OOWS-Handelsman), the Visual Analog Scale for Efficacy (VAS-E), and the Modified Clinical Global Impressions scales for efficacy and side effects. Efficacy will also be evaluated by study retention, completion rates, concomitant medication use, incidence of withdrawal-related Adverse Events (AEs), and subject treatment status 30 days post last dose of study medication. Qualitative urine drug screening will be done every other day to monitor for contraband (inpatient setting) or illicit (outpatient setting) drug use. Upon a subject's exit from the study, Study Discontinuation/End of Study assessments will be done.

During the study, study drug compliance will be documented in the source daily. During the first part of the study (Days 1-7), subjects will be inpatient and each dose of study medication will be administered by study site personnel and recorded in the source. Study medication will be dosed QID at 8 AM, 1 PM, 6 PM and 11 PM. During the second part of the study (Days 8-14), subjects who remain inpatient will be administered each dose of study medication by study site personnel and dosing will be captured in the source. Subjects who complete the second part of the study on an outpatient basis will return to the clinic daily for study assessments. During the open-label period, subjects will be dispensed 1-2 days worth of study drug, as needed to allow for flexibility in scheduling daily visits, to get them through until they are supposed to return the following day for additional study assessments and dosing.

Study medication will be held if vital signs meet any of the following criteria: Resting (sitting or recumbent, if required, for treatment of an adverse event): Systolic blood pressure \<90 mmHg and >20% below screen value; Diastolic blood pressure \<50 mmHg and >20% below screen value; Heart rate \<50 bpm and >20% below screen value; and Symptoms of hypotension and/or bradycardia (e.g., lightheadedness, dizziness, syncope).Orthostatic (after standing for 3 minutes): Systolic blood pressure diastolic blood pressure, or pulse >25% below recumbent values.

A subject will be discontinued from the study if any of the following criteria are met: Systolic blood pressure \<70 mmHg and >20% below screen value; Diastolic blood pressure \<40 mmHg and >20% below screen value; Heart rate \<40 bpm and >20% below screen value; QTc >500 msec or >25% above screen value for both males and females; Syncope; Subject misses more than 2 doses in 24 hours during Days 1-7 prior to meeting "completer" criteria (i.e., receives at least one dose of study medication on Day 7 and completed the 3.5-hour post-dose SOWS-Gossop assessments on Day 7); Subject misses a total of 6 doses during Days 1-7 prior to meeting "completer" criteria (i.e., receives at least one dose of study medication on Day 7 and completed the 3.5-hour post-dose SOWS-Gossop assessments on Day 7); Concomitant medication use (other than alumina, magnesia, and simethicone) for intolerable nausea and emesis.

Subjects should be discontinued from the study for any of the reasons listed below, and the event should be recorded as an Adverse Event (AE) and the subject followed until medically stabilized to the satisfaction of the attending physician: New onset of clinically significant abnormal ECG (e.g., second or third degree heart block or uncontrolled arrhythmia, prolonged QTcF interval); Persistent symptomatic hypotension (e.g., hypotension not responding to bed rest or fluids); Single occurrence of symptomatic bradycardia (as assessed by the Investigator, regardless of blood pressure) associated with chest pain, shortness of breath, or decreased level of consciousness; Persistent hypertension - blood pressure ≥185/110 mmHg recorded on 3 separate occasions taken at least 5 minutes apart AND within a 1-hour time period. If all 3 readings are ≥185/110 mmHg (either systolic ≥185 mmHg or diastolic ≥110 mmHg) the subject must be terminated; Medical Intervention for Cardiovascular Event: Any medical intervention (nonmedication or medication inclusive) used for the treatment of any cardiovascular event, with the exception of a positional intervention in subjects displaying hypotension; Any other clinically significant cardiovascular signs or symptoms that would place the subject at risk.

03

Conditions studied

  • Opioid Dependence
  • Acute Opioid Withdrawal Syndrome

Keywords

  • lofexidine
  • opioid dependence
  • acute withdrawal syndrome
  • opioid withdrawal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years of age.
  • Currently dependence, according to the Mini International Neuropsychiatric Interview (M.I.N.I.) [17, 18], on any opioid with a half-life similar to heroin or morphine, including Vicodin®, Lortab®, Lorcet®, Percocet®, Percodan®, Tylox®, or Hydrocodone (by any route of administration), or oxycodone (oxycodone and oxycodone time-released formulation when crushed and snorted, injected or swallowed after chewing).
  • Seeking treatment for opioid dependence.
  • Score of ≥2 on the Objective Opiate Withdrawal Scale (OOWS-Handelsman) at Baseline.
  • Reported use of heroin, morphine, or any opioid with a half-life similar to heroin or morphine for at least 21 of the past 30 days.
  • Urine toxicology screen positive for opioids but negative for methadone and buprenorphine.
  • Females of must agree to using methods and must have had documented proof.
  • Able to verbalize understanding of the consent form, able to provide written , verbalize willingness to complete study procedures, and pass the study consent quiz with 100% accuracy (if necessary, quiz may be administered more than one time).

Exclusion criteria

Exclusion Criteria:

  • Female subject who is pregnant or lactating.
  • Self-reported use of methadone or buprenorphine in the past 14 days.
  • Serious medical illnesses including, but not limited to: seizures, pancreatic disease, liver disease, exposure to a hepatitis virus, and positive hepatitis results.
  • Psychiatric disorder, based on the M.I.N.I., including but not limited to dementia or any disorder that, in the opinion of the study physician requires ongoing treatment that would make study participation unsafe or which would make treatment compliance difficult.
  • Self-reported acquired immune deficiency syndrome (AIDS) or self-reported (HIV) positive status and taking retroviral medications currently or within the past 4 weeks.
  • Abnormal cardiovascular exam at screening and before randomization, including any of the following: abnormal (ECG) (e.g., second or third degree heart block, uncontrolled arrhythmia, or interval greater than 450 msec for males and greater than 470 msec for females); heart rate less than 55 bpm or symptomatic bradycardia; systolic blood pressure (SBP) less than 95 mmHg or symptomatic hypotension; diastolic blood pressure (DBP) less than 65 mmHg; blood pressure (BP) greater than 155/95 mmHg; and prior history of myocardial infarction.
  • Clinically significant abnormal laboratory values.
  • Requiring any of the following medications currently or within the past 4 weeks: psychotropics (including sedatives/hypnotics, antidepressants, neuroleptics), prescription analgesics (excluding those listed in inclusion criterion #2 above), anticonvulsants, antihypertensives, antiarrhythmics, antiretroviral, and cholesterol lowering medications. Nicotine replacement therapy (patch, inhaler, gum, or nasal spray) will be allowed for nicotine-dependent subjects. Note: Use of a short-acting benzodiazepine (e.g., oxazepam) for insomnia during Days 8 14 will not disqualify a subject.
  • Currently dependent (based on the M.I.N.I.) on any psychoactive substance (other than that listed in inclusion criterion #2, caffeine or nicotine) that requires detoxification.
  • Donated blood within the last 8 weeks.
  • Participated in an drug study within the past 3 months.
  • Has "poor" veins that even a single venipuncture cannot be obtained during screening.
  • Active tuberculosis (positive tuberculin test and/or confirmatory diagnostic chest x-ray).
  • Active syphilis.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
603 participants (actual)

Study arms

  • Active comparator
    Lofexidine HCl (2.4mg dose)

    225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.

    Drug: Lofexidine HCl · Drug: Placebo

  • Active comparator
    Lofexidine HCl (3.2mg dose)

    225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.

    Drug: Lofexidine HCl

  • Placebo comparator
    Placebo

    150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.

    Drug: Placebo

  • Other
    Open Label Lofexidine HCl

    During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.

    Drug: Open Label Lofexidine HCL

Interventions

  • Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.

  • DrugPlacebo

    Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.

  • DrugOpen Label Lofexidine HCL

    Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.

06

What researchers measure

Primary outcomes

  1. Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores

    The SOWS-Gossop was completed by the mITT population subject at baseline, once daily at 3.5 hours after the first dose of the study medication on Days 1 to 7. It consists of 10 items that are scored on a 4-point scale; 0=none, 1=mild, 2=moderate, and 3=severe. The overall score is the simple sum of the 10-item scores (minimum overall score of 0, maximum score of 30). Higher individual scores on the scale indicate greater symptom severity. However, as the outcome measure is a difference from placebo, a lower number indicates a better outcome. mITT population: all randomized subjects who received at least 1 dose of study medication

    Time frame: Days 1 through 7

Secondary outcomes

  1. Completion Status

    The percentage of subjects in each treatment arm who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7.

    Time frame: Day 7

07

Results

Posted Feb 4, 2021

Participant flow

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneDB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboOL: All Lofexidine HCl
Started2292221510
Completed9588420
Not completed1341341090
Open-label Phase
Participant flow — Open-label Phase
MilestoneDB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboOL: All Lofexidine HCl
Started00083
Completed00070
Not completed00013

Outcome measures

PrimaryDifference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores

The SOWS-Gossop was completed by the mITT population subject at baseline, once daily at 3.5 hours after the first dose of the study medication on Days 1 to 7. It consists of 10 items that are scored on a 4-point scale; 0=none, 1=mild, 2=moderate, and 3=severe. The overall score is the simple sum of the 10-item scores (minimum overall score of 0, maximum score of 30). Higher individual scores on the scale indicate greater symptom severity. However, as the outcome measure is a difference from placebo, a lower number indicates a better outcome. mITT population: all randomized subjects who received at least 1 dose of study medication

Time frame:
Days 1 through 7
Reported as:
Mean · score on a scale
Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores
score on a scaleDB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: Placebo
Day 17.8 ± 6.007.6 ± 6.759.4 ± 6.81
Day 210.2 ± 6.839.9 ± 7.3813.9 ± 8.29
Day 37.6 ± 5.537.4 ± 6.3410.9 ± 6.76
Day 45.7 ± 5.325.5 ± 5.369.2 ± 6.81
Day 54.7 ± 4.604.5 ± 4.966.4 ± 5.91
Day 63.6 ± 3.973.2 ± 4.104.4 ± 5.80
Day 72.7 ± 3.452.3 ± 3.232.7 ± 4.60
Statistical analysis
  • DB: Lofexidine HCl 2.4mg Dose vs DB: Placebo · Pattern Mixture Model · p = 0.0166
  • DB: Lofexidine HCl 3.2mg Dose vs DB: Placebo · Pattern Mixture Model · p = 0.0033
SecondaryCompletion Status

The percentage of subjects in each treatment arm who receive at least one dose of study medication on Day 7 and complete the 3.5 hour post-dose SOWS-Gossop assessment on Day 7.

Time frame:
Day 7
Reported as:
Count of participants · Participants
Completion Status
ParticipantsDB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: Placebo
Yes/Complete958842
No/Did Not Complete134134109

Adverse events

Collected over Through study completion (14 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB: Lofexidine HCl 2.4mg Dose0/229 (0%)0/229 (0%)216/229 (94.3%)
DB: Lofexidine HCl 3.2mg Dose1/222 (0.5%)5/222 (2.3%)211/222 (95%)
DB: Placebo0/151 (0%)2/151 (1.3%)134/151 (88.7%)
OL: All Lofexidine HCl0/83 (0%)0/83 (0%)46/83 (55.4%)
Most frequent serious events
Most frequent serious events
EventDB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboOL: All Lofexidine HCl
SyncopeNervous system disorders0/2292/2220/1510/83
Acute hepatitis CInfections and infestations0/2290/2221/1510/83
Electrocardiogram QT prolongedInvestigations0/2290/2221/1510/83
OverdoseInjury, poisoning and procedural complications0/2291/2220/1510/83
Toxicity to various agentsInjury, poisoning and procedural complications0/2291/2220/1510/83
Suicidal ideationPsychiatric disorders0/2291/2220/1510/83
Most frequent other events
Showing 10 of 25
Most frequent other events
EventDB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboOL: All Lofexidine HCl
InsomniaPsychiatric disorders117/229123/22273/1514/83
Orthostatic hypotensionVascular disorders67/22994/2227/1514/83
BradycardiaCardiac disorders54/22970/2228/1513/83
HypotensionVascular disorders69/22967/2222/1517/83
PainGeneral disorders51/22942/22236/1514/83
DiarrhoeaGastrointestinal disorders51/22948/22235/1515/83
DizzinessNervous system disorders44/22951/2224/1513/83
NauseaGastrointestinal disorders50/22927/22232/1510/83
MyalgiaMusculoskeletal and connective tissue disorders30/22922/22225/1511/83
VomitingGastrointestinal disorders23/22919/22224/1511/83

Baseline characteristics

Demographic Characteristics of modified intent-to-treat "mITT" Population (excludes one subject who randomized but never received study drug)

Age, Continuous
Age, Continuous(years)DB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboTotal
Mean35 ± 10.835 ± 10.536 ± 11.935 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)DB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboTotal
Female676444175
Male162158107427
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboTotal
Hispanic or Latino33282283
Not Hispanic or Latino196194129519
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboTotal
American Indian or Alaska Native0224
Asian1315
Native Hawaiian or Other Pacific Islander0235
Black or African American544826128
White169158117444
More than one race0000
Unknown or Not Reported59216
Body weight
Body weight(kg)DB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboTotal
Mean76.0 ± 16.8876.1 ± 16.5976.0 ± 14.9476.1 ± 16.29
BMI (kg/m^2)
BMI (kg/m^2)(kg/m^2)DB: Lofexidine HCl 2.4mg DoseDB: Lofexidine HCl 3.2mg DoseDB: PlaceboTotal
Mean25.1 ± 4.7125.1 ± 5.3225.1 ± 4.6325.1 ± 4.92
08

Study locations

18 sites
  • Clovis, California 93611, United States
  • Escondido, California 92025, United States
  • San Diego, California, United States
  • Miami, Florida 33136, United States
  • Orlando, Florida 32806, United States
  • Atlanta, Georgia 30308, United States
  • Oak Park, Illinois 60301, United States
  • Lake Charles, Louisiana 70629, United States
  • Baltimore, Maryland 21229, United States
  • Flowood, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Dayton, Ohio, United States
  • Mason, Ohio 45050, United States
  • Austin, Texas 78731, United States
  • Dallas, Texas 75208, United States
  • DeSoto, Texas 75115, United States
  • Orem, Utah 84058, United States
  • Salt Lake City, Utah 84106, United States
09

References and documents

Publications

  • Alam D, Tirado C, Pirner M, Clinch T. Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials. J Drug Assess. 2020 Jan 8;9(1):13-19. doi: 10.1080/21556660.2019.1704416. eCollection 2020. PubMed 32002194 ↗
  • Darpo B, Pirner M, Longstreth J, Ferber G. Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal. Drug Alcohol Depend. 2019 Dec 1;205:107596. doi: 10.1016/j.drugalcdep.2019.107596. Epub 2019 Sep 27. PubMed 31606589 ↗
  • Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW; CLEEN-SLATE Team. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial. J Addict Med. 2019 May/Jun;13(3):169-176. doi: 10.1097/ADM.0000000000000474. PubMed 30531234 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2021, 6 years 3 months after primary completion. A results delay was requested in Feb 2015.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2013
First posted
May 27, 2013
Start
Jun 2013
Primary completionActual
Nov 2014
CompletionActual
Dec 2014
Results delay requested
Feb 12, 2015
Results first posted
Feb 4, 2021
Last update
Mar 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01863186
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
May 27, 2013
Start date
Jun 2013
Primary completion
Nov 2014
Completion
Dec 2014
Results posted
Feb 4, 2021
Last update
Mar 22, 2022

Study contacts

Charles W Gorodetzky, MD, PhD
principal investigator · US WorldMeds

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lofexidine

Start the discussion